Mednet Logo
HomePediatric Hematology/Oncology
Pediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

How do you approach hormone replacement therapy for premenopausal patients following pelvic radiation therapy?

2
1 Answers

Mednet Member
Mednet Member
Obstetrics & Gynecology · Dana-Farber Cancer Institute

Most patients who undergo pelvic radiation will become menopausal. Physiologically, the outcome is similar to surgical menopause because sufficient doses of radiation result in complete loss of ovarian function. In contrast, after natural menopause, the ovaries continue some types of endocrine funct...

What is the role of local control +/- whole lung irradiation in a patient with relapsed/refractory Ewing sarcoma to the hilum plus multiple lung nodules?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · The Ohio State University - James Cancer Hospital and Solove Research Institute

I would boost residual thoracic disease to at least the usual Ewings gross disease dose of 55.8 (total, including WLI dose). Doses in this range are well known to be safe in the thorax and this multiply relapsed disease is likely to be more treatment refractory than primary disease. SBRT boost seems...

How should elevated PT of unclear etiology and significance be evaluated?

2 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

Mild prolongation of the prothrombin time (PT) may represent a normal ‘outlier’. If there is no obvious explanation for a moderate to marked prolongation of the PT (for example, anticoagulation therapy effect, liver disease, nutritional deficiency like vitamin K deficiency. then the next step is to ...

How would you approach a low to moderate titer of one of the APLS antibodies in a patient with a strong family history but no personal history of thrombosis?

2 Answers

Mednet Member
Mednet Member
Rheumatology · UTMB Health

I would repeat these tests in about 12 weeks or so. Certain infections can transiently induce positive antiphospholipid antibodies, usually non-pathogenic, with certain exceptions.

Do you typically see peripheral neuropathy in patients with castleman syndrome?

1
2 Answers

Mednet Member
Mednet Member
Neurology · Cedars-Sinai Medical Center

Castleman's is a rare disorder. It has been associated with POEMS in which severe neuropathy is part of the syndrome, but is not as common an association as myeloma. But neurologists only see the patients who have neurologic symptoms. My brief look at review articles on Castleman's suggests that POE...

Do you switch from imatinib to another TKI in patients with chronic phase CML who develop renal insufficiency?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Georgia Cancer Center at Augusta University

Imatinib has been associated with a decline in GFR. It is not certain (and probably doubtful) that this represents kidney damage. If no other causes can be identified, a change could be appropriate. Bosutinib has been associated with a similar decline so nilotinib or dasatinib might be better option...

When would you consider tapering glucocorticoids in a patient with ICI-associated myocarditis?

2 Answers

Mednet Member
Mednet Member
Cardiology · Memorial Sloan Kettering Cancer Center

Once troponins start to decrease, I start the steroid taper and follow troponin levels. If they rise, I slow the taper. I also get serial ECGs, esp if there were arrhythmia manifestations of myocarditis. Don't forget to assess for the need for PJP prophylaxis with Bactrim or pentamidine and PPI sinc...

Based on recently published data from COG ANHL12P1, how will you use crizotinib in pediatric and AYA patients with ALK+ anaplastic large cell lymphoma?

3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Medical City Children’s Hospital

I would discuss brentuximab (plus ALCL chemo backbone) with newly diagnosed ALCL with patients and families in the absence of any open trials. The published COG data looks favorable but hasn't been shown in a randomized setting to improve EFS/OS. With the VTE data (and the availability of Brentuxima...

When patients develop headaches from luspatercept, do they tend to improve over time?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Taussig Cancer Institute

I've seen two common scenarios with this. One is headaches related to hypertension as a result of luspatercept. By treating the hypertension, the headaches often improve. If the headaches are in the absence of hypertension, I do use a low dose beta blocker to see if it helps, and have had some resul...

What precautions do you take prior to CABG in a patient with sickle cell trait?

1 Answers

Mednet Member
Mednet Member
Hematology · Boston University School of Medicine

Surgery and anesthesia are safe in sickle cell trait (HbAS) when normal precautions are followed. In patients with HbAS and control subjects, the frequency of anesthetic, surgical, and postoperative complications was similar; however, most patients were young, and few thoracic procedures were includ...